- Home
- CZNC vs FENC Comparison
CZNC vs FENC Comparison
Compare CZNC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | FENC |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 384.0M |
| IPO Year | 2009 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CZNC | FENC |
|---|---|---|
| Price | $25.01 | $10.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 43.0K | ★ 128.3K |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.81 | 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $38.42 | $62.55 |
| Revenue Next Year | $4.97 | $42.10 |
| P/E Ratio | ★ $31.20 | $177.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.87 | $5.65 |
| 52 Week High | $26.37 | $13.25 |
Technical Indicators
Market Signals| Indicator | CZNC | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 48.69 |
| Support Level | $24.89 | $9.84 |
| Resistance Level | $26.16 | $11.29 |
| Average True Range (ATR) | 0.52 | 0.50 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 58.08 | 56.54 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.